SYNGENEIC
MODELS
DOMESTIC QUALITY. EXCEPTIONAL VALUE.
Rincon runs high-quality in vivo cancer efficacy studies at our U.S. facilities, keeping your work close, protecting your IP, and making communication direct and easy. We bring the scientific experience you’d expect from a major CRO without all the layers and overhead.
DIRECT ACCESS
Work directly with the PhD running your study—not a rotating account manager. We stay responsive, flexible, and hands-on throughout the study.
Syngeneic tumor models use tumor cell lines derived from the same species as the host animal, allowing the immune system to remain intact. These models are well suited for evaluating immuno-oncology agents as monotherapies or in combination with other anti-cancer treatments.
Additional capabilities include:
-
Custom study designs
-
Fluorescent imaging
-
MTD and tolerability studies
-
Preclinical drug formulation
-
Tumor and organ collection
-
Histology
-
Pharmacodynamic studies, including ELISA, Luminex, PCR, sequencing, and flow cytometry
-
Complementary cell-based in vitro assays supporting in vivo studies
See below for our available syngeneic models or to request a quote.
SYNGENEIC
cell lines
Cell line | Organ | Weeks from stratification to termination (average) | Growth Curve |
|---|---|---|---|
4T1 | Breast | 4 | |
A20 | Blood | N/A | |
AB22 | Lung | N/A | |
B16-F10 | Skin | 2 | |
CT26 | Colon | 2.5 | |
CT26.CL25 | Colon | 2.5 | |
Cloudman S91 | Skin | N/A | |
Colon-26 (MC26) | Colon | 4 | |
D4M3A | Skin | 2 | |
EMT6 | Breast | 5 | |
Lewis Lung LLC1 | Lung | 3 | |
MBT-2 | Bladder | 5.5 | |
MC38 | Colon | 4 | |
P388 | Blood | N/A |
*Additional cell lines are possible. Contact us to discuss your model of interest.
QUOTE REQUEST FORM
syngeneic studies
Please fill out the form below
We will respond with a quote within one business day
MEET OUR SCIENTIFIC DIRECTOR
Bret Stephens, PhD
Bret brings more than 20 years of in vivo biology and cancer drug-discovery experience spanning pharmaceutical and academic research.
At Rincon, Bret remains directly involved in study design and execution—part of our approach of giving clients direct access to the scientists responsible for their work.
Dr. Stephens received his PhD in Molecular Biology from the University of Arizona.
Previous to joining Rincon Bio, Dr. Stephens worked at Tolero Pharmaceuticals, Huntsman Cancer Institute (University of Utah), and the BioDesign Institute (Arizona State University), where he focused on cancer small molecule drug development.
ABOUT US
We built Rincon around a few things we think matter: strong science, exceptional value, rapid study initiation, and direct access to the people doing the work.
We’ve worked in pharma, academia, and major CROs, so we’ve seen both what works and what gets in the way. Rincon keeps the focus where it belongs: experienced scientists, well-run studies, and useful data.
We specialize in xenograft and syngeneic cancer models, and our team brings experience from thousands of in vivo studies for biotech, pharmaceutical, and academic groups around the world. We stay close to the work and keep the process straightforward from study design through final report.
We’re not trying to be the biggest CRO. We’re aiming to be the one you want to work with.
Email: info@rinconbio.com
Tel: 760-713-6613
Utah:
3900 N Traverse Mountain Blvd
Suite 100
Lehi, UT 84043
California:
3156 Vista Way, Suite 220
Oceanside, CA 92056